Key Trends Reshaping the Antipsychotic Drugs Market: Advancements In Subcutaneous Antipsychotic Injections For Enhanced Patient Compliance And Efficacy Industry Transformation

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Antipsychotic Drugs Market Size Growth Forecast: What to Expect by 2025?
In recent years, the antipsychotic drugs market has witnessed substantial growth. The market, forecasted to increase from $19.5 billion in 2024 to $21.25 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 9.0%. The historic growth rate is linked to the increasing occurrence of mental health disorders, the evolution of second-generation antipsychotics, an aging population, betterment in healthcare framework, and significant investment in research and development.

How Will the Antipsychotic Drugs Market Size Evolve and Grow by 2029?
Anticipated vigorous expansion is on the cards for the antipsychotic drugs market in the forthcoming years. The market is projected to escalate to ""$30.39 billion in 2029,"" registering a compound annual growth rate (CAGR) of 9.4%. This upswing during the forecast period is ascribed to the growing prevalence of schizophrenia and bipolar disorder, encouraging governmental policies and funding, an increased need for personalized medicine, efforts towards side-effects minimization, and an upsurge in mental health advocacy and support organizations. Significant forecast period trends encompass the inclusion of digital health instruments for tracking, discovery of innovative mechanisms of action, a more prominent focus on combination therapies, the use of pharmacogenomics for customized treatments, and a stress on patient-focused drug development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

What Drivers Are Propelling the Growth of Antipsychotic Drugs Market Forward?
The rise in mental disorder cases is anticipated to drive the antipsychotic drug market growth. Mental disorders, or mental illnesses, are conditions that affect a person's thinking, behavior, mood, and overall mental health. Factors such as stress levels, societal pressures, genetics, biochemical imbalances, neurodevelopmental disorders, and physical health conditions can influence these cases. Antipsychotic medications serve to regulate mental disorders by altering neurotransmitter activity, mainly dopamine and serotonin. This helps alleviate psychotic symptoms, stabilize mood, and enhance cognitive and emotional function. A survey implemented by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US public health government agency, showed that nearly 6% of adults aged 18 and above, equating to about 15.4 million individuals, were suffering from Serious Mental Illness (SMI) in November 2023. Additionally, figures released by the Australian Institute of Health and Welfare in September 2024 anticipated a more than two-fold increase in dementia cases in Australia from approximately 411,100 in 2023 to 849,300 by 2058, affecting roughly 315,500 men and 533,800 women. Hence, the surging prevalence of mental disorders is fuelling the antipsychotic drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

What Trends Will Shape the Antipsychotic Drugs Market Through 2029 and Beyond?
Leading corporations within the antipsychotic drug market are focusing their efforts on producing innovative medical products, such as subcutaneous atypical antipsychotic injections. These advanced forms of psychiatric drugs, which are administered beneath the skin, are designed to treat mental health disorders, stabilize blood levels, and enhance symptom management. The newly developed products prove to be more effective and comfortable for patients in comparison to older oral medications. For example, in April 2023, Israeli pharmaceutical company, Teva Pharmaceutical Industries Ltd., partnered with MedinCell SA, a bioproduct and pharmaceutical preparation manufacturer from France, to introduce UZEDY. The US Food and Drug Administration has approved UZEDY, an extended-release injectable version of risperidone, which can be conveniently administered once or twice a month. UZEDY's development leverages the exclusive SteadyTeq technology of MedinCell, ensuring a consistent release of the drug and attaining therapeutic efficacy within 6-24 hours after being administered. Clinical trials have shown that UZEDY can reduce the risk of a schizophrenia relapse by up to 80% compared to the placebo group. This novel development is aimed at overcoming the common problems of medication adherence linked to oral antipsychotics, which frequently results in relapse.

What Are the Key Segments in the Antipsychotic Drugs Market?
The antipsychotic drugs market covered in this report is segmented -

1) By Therapeutic Class: First Generation, Second Generation, Third Generation
2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:
1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines
2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone
3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

Who Are the Key Players Shaping the Antipsychotic Drugs Market's Competitive Landscape?
Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

What Geographic Markets Are Powering Growth in the Antipsychotic Drugs Market?
North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18780

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

"

#Reach Out to Us#

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.